Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15389825 | 0.91 | BACE1 (0.42) | BACE1 | |
| SCHEMBL3940682 | 0.86 | BACE1 (0.44) | BACE1 | |
| SCHEMBL7234154 | 0.85 | CYP3A4 (0.41) | BACE1 | |
| SCHEMBL5467148 | 0.85 | BACE1 (0.39) | BACE1CD44 | |
| SCHEMBL23908366 | 0.84 | DUT (0.33) | BACE1CD44 | |
| SCHEMBL5465261 | 0.84 | IDO1 (0.41) | BACE1 | |
| SCHEMBL20189141 | 0.83 | IDO1 (0.44) | BACE1 | |
| SCHEMBL5462578 | 0.81 | IDO1 (0.45) | BACE1 | |
| SCHEMBL23908432 | 0.81 | DUT (0.37) | BACE1CD44 | |
| SCHEMBL6702684 | 0.81 | BACE1 (0.41) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | BACE1 4232/4885CD44 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.